|
시장보고서
상품코드
2052544
신장암 치료제 시장 : 치료법별, 약리학적 분류별, 유통 채널별, 지역별Kidney Cancer Drugs Market, By Therapy, By Pharmacological Class, By Distribution Channel, By Geography |
||||||
신장암 치료제 시장은 2026년에 77억 7,000만 달러로 추정되며, 2033년까지 119억 2,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 77억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 6.30% | 2033년 시장 규모 예측: | 119억 2,000만 달러 |
의약품 분석 검사란 신세포암으로도 알려진 신장암을 확진 진단하기 위해 과학적인 기술이나 방법을 사용하는 것을 말합니다. 신장암은 전 세계적으로 가장 흔한 암 중 하나가 되고 있습니다. 추정에 따르면, 전 세계적으로 매년 40만 명 이상의 신규 확진자가 발생하고 있습니다. 신장암과 관련된 위험 요인으로는 흡연, 비만, 유전적 요인, 특정 독소 노출 등이 있습니다. 초기에는 증상이 나타나지 않을 수도 있지만, 일부 환자에서는 혈뇨, 측복부 통증 또는 복부 덩어리가 나타날 수 있습니다. 치료법으로는 국소 병변에 대한 부분 신절제술, 근치적 신절제술부터 진행성 질환에 대한 표적치료, 면역요법까지 다양합니다. 전반적으로 세계 신장암 치료제 시장은 질병 발생률 증가, 첨단 치료법에 대한 환자 접근성 향상, 탄탄한 신약 파이프라인 등의 요인으로 인해 향후 몇 년 동안 크게 성장할 것으로 예상됩니다.
시장 역학:
세계 신장암 치료제 시장은 전 세계 신세포암 유병률 증가에 힘입어 성장하고 있습니다. 고령인구 증가, 비만율 증가, 직장에서의 유해물질 노출 증가 등 위험요인의 확대가 발병률 상승에 기여하고 있습니다. 또한, 선진국의 고품질 표적 치료제 및 면역치료에 대한 환자 접근성이 개선되고 있는 점도 시장 성장을 뒷받침하고 있습니다. 동시에 수술, 방사선 치료, 약물 치료를 병행하는 장기적인 치료로 인해 환자는 더 오랜 기간 동안 유지 요법에 의존할 수밖에 없습니다. 시장에는 큰 성장 기회가 예상되는 반면, 주요 의약품의 특허만료와 제네릭 의약품의 시장 진입 등의 요인이 주요 개발사들의 수익원을 저해할 수 있습니다. 또한, 개발도상국에서의 높은 가격과 경제적 부담의 문제는 더 광범위한 시장 접근을 제한하고 있습니다. 그럼에도 불구하고, 다양한 질병 경로를 타겟으로 하는 임상시험 중인 분자의 탄탄한 파이프라인은 향후 시장 확대 가능성을 보여주고 있습니다.
본 조사의 주요 특징
- 이 조사에서는 각 부문의 잠재적 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 세계 신장암 치료제 시장의 주요 기업 프로파일을 다음과 같은 매개 변수를 기반으로 작성되었습니다 : 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계 신장암 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 신장암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 신장암 치료제 시장 : 치료법별, 2021-2033년
제5장 세계의 신장암 치료제 시장 : 약리학적 분류별, 2021-2033년
제6장 세계의 신장암 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 신장암 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌 및 조사 방법
KSMKidney Cancer Drugs Market is estimated to be valued at USD 7.77 Bn in 2026 and is expected to reach USD 11.92 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.77 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.30% | 2033 Value Projection: | USD 11.92 Bn |
Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.
Market Dynamics:
The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.
Key Features of the Study
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market
Detailed Segmentation
- By Therapy (Revenue, USD Bn, 2021 - 2033)
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- By Pharmacological Class (Revenue, USD Bn, 2021 - 2033)
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG (Genentech, Inc.)
- Bayer AG
- Exelixis, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacological Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Kidney Cancer Drugs Market, By Therapy, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cytokines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Kidney Cancer Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Kidney Cancer Drugs Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Roche Holding AG (Genentech, Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Exelixis, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aveo Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen Biopharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott Laboratories Source
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Calithera Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Active Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Immatics Biotechnologies GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Karyopharm Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
